0001209191-20-059273.txt : 20201118 0001209191-20-059273.hdr.sgml : 20201118 20201118195627 ACCESSION NUMBER: 0001209191-20-059273 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201116 FILED AS OF DATE: 20201118 DATE AS OF CHANGE: 20201118 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LEONARD JOHN M CENTRAL INDEX KEY: 0001563584 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37766 FILM NUMBER: 201326723 MAIL ADDRESS: STREET 1: C/O INTELLIA THERAPEUTICS INC STREET 2: 40 ERIE STREET, SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER NAME: FORMER CONFORMED NAME: LEONARD JOHN M. DATE OF NAME CHANGE: 20121204 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Intellia Therapeutics, Inc. CENTRAL INDEX KEY: 0001652130 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 364785571 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 40 ERIE STREET STREET 2: SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-285-6200 MAIL ADDRESS: STREET 1: 40 ERIE STREET STREET 2: SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-11-16 0 0001652130 Intellia Therapeutics, Inc. NTLA 0001563584 LEONARD JOHN M C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET; SUITE 130 CAMBRIDGE MA 02139 1 1 0 0 President and CEO Common Stock 2020-11-16 4 M 0 20000 14.58 A 487352 D Common Stock 2020-11-16 4 S 0 20000 34.00 D 467352 D Common Stock 58415 I By Trust Stock Option (right to buy) 14.58 2020-11-16 4 M 0 20000 0.00 D 2028-12-17 Common Stock 20000 220000 D The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Shares held by the John M. Leonard 2015 Irrevocable Trust. The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 110,000 shares as of November 16, 2020. /s/Jose Rivera Attorney-In-Fact 2020-11-18